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Abstract
Background: Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy
(OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge
on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-
perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and
assesses changes in these scores at 1-year follow up.
Methods: We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT
patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-
perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from “no problems” to
“extreme problems”). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and
compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100).
Results: Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22)
compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L
index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for
female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were
observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index
value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively.
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Conclusion: The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the
general population, and lower than what has been found among other severe somatic and psychiatric conditions.
Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor
HRQoL.
Keywords: Health related quality of life, Quality of life, EQ-5D, Opiate substitution therapy, Opioid agonist therapy,
Opioid dependence, Epidemiology
Background
Opioid dependence is a severe chronic relapsing disorder
consisting of a cluster of physiological, behavioral, and
cognitive phenomena [1]. Worldwide, opioid use disor-
ders affect over 16 million people and are responsible
for over 120.000 deaths per year [2]. Of all illegal drugs,
opioids denote the highest disease burden, have the
highest demand for treatment, contribute to substantial
increased healthcare costs, and have given rise to a
marked increase in opioid related deaths in the last dec-
ade [3–5]. People with opioid use disorders suffer not
only from a shorter life-span as compared to the general
population, but also severe social marginalization and
long-term impairments in most aspects of their lives [6].
Research consistently shows that people with opioid use
disorders have inferior quality of life (QoL) compared to
the general population [7, 8]. This is partly explained by
the extensive co-occurrence of substance use disorder
and mental disorders, which both seem underdiagnosed
and undertreated [9], in addition to high prevalence of
somatic disorders such as chronic hepatitis C of almost
50% [10]. Epidemiological studies suggest a prevalence
of around 27% for anxiety disorders, 35% for affective
disorders, 30% for attention-deficit hyperactivity dis-
order, and 51% for personality disorders in patients with
substance use disorders [11–13]. However, prevalence
may be even higher in clinical studies as people with se-
vere problems are more likely to seek help; studies have
found prevalence of around 70% for one or more per-
sonality disorder [14] and around 66% for childhood
trauma among people with substance use disorders [15],
and at least one comorbid psychiatric disorder in ap-
proximately 80% of patients on opioid agonist therapy
(OAT) [16].
Increased focus on, and availability of harm reduction
programs, such as OAT have lowered the demand for
heroin in Western Europe including Norway [5]. OAT is
an evidence-based medical intervention that reduces
illicit opioid use, improves patients’ health and reduces
crude mortality rates significantly [3, 17–20]. For in-
stance, results of 22 pooled longitudinal cohort studies
showed a crude mortality rate for patients on OAT of
0.90 per 100 person years, compared to 1.63 when OAT
was ceased and 4.91 for untreated periods [21]. Most
research on OAT has emphasized on crude mortality
rate, abstinence and retention in treatment, rather than
what may be most important for each individual patient;
personal wellbeing. In turn, several researchers argued
that health related quality of life (HRQoL) should be in-
cluded as an outcome when evaluating substance use
and OAT treatment [22–25]. Thus, to evaluate real life
outcome of OAT, changes in objective and self-
perceived health, including the individual’s own experi-
ence, should be examined. In addition, for more individ-
ualized OAT treatment and management, it is important
to understand the relationship between clinical and
demographic characteristics and HRQoL.
Factors associated with poor HRQoL among OAT pa-
tients are older age, female gender, and mental and phys-
ical comorbidity [7, 26, 27]. There is building evidence
that HRQoL is substantially lower among people with opi-
oid dependence and that HRQoL improves at OAT initi-
ation and during the first few months of treatment [27–
30]. However, a recent systematic review suggests there is
still limited knowledge regarding HRQoL outcomes in
OAT treatment programs and HRQoL outcomes are
rarely used [22]. Many of the previous studies are cross-
sectional rather than longitudinal designs, offers few par-
ticipants and with non-validated HRQoL measures for
opioid dependence, which make comparisons difficult
across opioid dependence and other diseases.
The principal aim of this study is to evaluate the
HRQoL and self-perceived health of a large cohort of
long-term patients with opioid dependence enrolled in
an integrated OAT program in Norway. The HRQoL of
OAT patients will also be compared to that of the gen-
eral population in Norway. Finally, an assessment of
changes in HRQoL and self-perceived health at one-year
follow-up will be conducted.
Methods
Study design and setting
This study is a nested prospective cohort study linked to
the Integrated Treatment of Hepatitis C study (INTRO-
HCV) [31]. The observational study recruited partici-
pants from May 2017 until January 2020 [31]. HRQoL
baseline data was collected at the first OAT health as-
sessment, and follow-up data was collected one-year
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after baseline for each patient. Trained research nurses,
who were not responsible for clinical patient follow-up,
collected the research data via structured patient inter-
views. The data was recorded directly in an electronic
data entry system (CheckWare). The study took place in
Bergen and Stavanger, which are cities in southwestern
parts of Norway with around 280,000 and 130,000 in-
habitants each. The target population was individuals
with opioid dependence who received OAT treatment
and care in all together nine OAT outpatient clinics.
The clinics have adopted an integrated treatment and
care model where patients are charted on a nearly daily
basis by health professionals; including social workers,
specialized and general nurses, psychologists, and physi-
cians specialized in addiction medicine. OAT medica-
tions include mostly methadone or buprenorphine-based
medications, often with directly observed intake [32].
Study sample
The study sample included individuals diagnosed with
opioid dependence according to International Classifica-
tion of Diseases version 10 (ICD-10) [33], currently en-
rolled in OAT treatment, aged 18 years or older, and
have given a written informed consent to participate in
the study. Individuals were eligible for inclusion regard-
less of the type of OAT medication or administration
form. Remuneration, of around euro 20, was provided
once for the participants upon inclusion to participate in
the study. Of the 900 patients invited, a total of 609
(68%) patients completed the EQ-5D-5L questionnaire
at baseline, and of those, 245 (40%) were followed up
with a follow-up questionnaire approximately 1 year
after the first visit. Nineteen patients (2%) were excluded
because they did not complete the interview or due to
missing data of the EQ-5D-5L instrument The mean
time between the first and second annual OAT assess-
ment was 375 days (95% confidence interval (CI): 359–
392 days). See Table 1 for details on clinical and demo-
graphic characteristics and additional file 1 for flowchart
of study sample.
Instruments
Health related quality of life: EQ-5D-5L
The EQ-5D-5L instrument is a widely used generic
measure of HRQoL [34] and validated for opioid use dis-
orders [35, 36]. It consists of two components. The first
descriptive system evaluates health in five dimensions
(Mobility, Self-care, Usual activities, Pain/Discomfort,
Anxiety/Depression). Each dimension has five levels of
response, ranging from no problems, slight problems,
moderate problems, severe problems, to extreme prob-
lems [37]. The second part of EQ-5D-5L entails a visual
analogue scale (VAS) where the respondent rates the
self-perceived health from 0 (worst health imaginable) to
100 (best health imaginable) [37]. A systematic review
supports the use of the EQ-5D-5L in a broad range of
patients [38]. We therefore selected this instrument to
assess the HRQoL of patients in OAT and to compare
their HRQoL to the general population.
Statistical analysis
Responses to the five HRQoL dimensions are coded as a
five-digit code, which represents a numerical description
of a health state. The digits have no arithmetic proper-
ties and therefore a single summery number (an index
value) needs to be arrived by applying a formula with an
appropriate value set, which is a representative sample
of the general population. The index value then repre-
sents how good or bad a health state is according to the
preferences of the general population, ranging from 1
(full health) to 0 (dead, with negative values indicating
health states worse than death) [37]. In the absence of a
Norwegian value set, we applied an EQ-5D-5L value set
for UK, i.e. the societal preference weights for the health
state, to determine the EQ-5D-5L index values for each
health state in the OAT cohort [39]. Summary statistics
were derived, including proportions and number of pa-
tients for the five EQ-5D-5L dimensions by age, gender
and OAT medications. The EQ-VAS score was summa-
rized descriptively by mean, standard deviation (SD),
minimum and maximum as the data was not particularly
skewed. A paired t-test of means for the 245 patients
with two time points was used in the analysis to investi-
gate whether there was any statistical significance in EQ-
5D-5L between the measurements. An ANCOVA model
for EQ-VAS changes from baseline to the next OAT
health assessment was conducted where place and treat-
ment were fixed effects and baseline covariate. If data
were missing from more than one dimension partici-
pants were excluded. Altogether eight patients missed
data on one dimension at baseline but were included in
the analyses. There were no missing data from EQ-5D-
5L follow-up or EQ-VAS. To estimate the unbiased
treatment effects from baseline to follow-up we used an
inverse probability weighted method as we had
follow-up data for a subgroup. We calculated popula-
tion weights based on age, gender and how many
times OAT medication was collected during a week
in a binominal regression model with follow-up values
as the dependent variable. More weight was given to
cases with valid data, which were associated with
highest probability of having missing data, and less
weight was given to cases with lowest probability of
missing. The mean for the population weights was 1.0
(SD 0.12) in our model. Statistical significance was set
at p < 0.05 level. All analyses were made with STATA
SE 16.0.
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Results
Baseline characteristics of study sample
The patients were predominantly male (71%) with a
mean (SD) age of 44 years (10). The age range of the
study sample was 23–74 years. Most received
buprenorphine-based medication (60%) followed by
methadone (38%). Duration in OAT treatment ranged
from 0 to 25 years, with a mean (SD) of 7.9 (5.4) years.
Results therefore reflects HRQoL of patients that have
received OAT over a long period of time. Of the partici-
pants, 45% had completed secondary school and 40%
completed high school. Almost 80% received either dis-
ability pension or social benefits as main source of in-
come. Of the 152 OAT patients with children under 18
years, 21% reported they had no visiting rights (Table 1).
The distributions of sociodemographic variables were
similar for the baseline- and the follow-up samples.
However, the proportion of males increased from 71 to
76% in the follow-up sample and mean (SD) age in-
creased from 44 (10) to 45 (10) years compared to the
sample at baseline.
HRQoL of OAT patients at baseline
The distributions of unadjusted EQ-5D-5L scores are
presented as norm sets according to gender, age groups,
and OAT medications (Fig. 1). Overall, mean scores for
the five dimensions were 1.7 (95% CI: 1.6–1.8) for mo-
bility, 1.3 (95% CI: 1.2–1.3) for self-care, 1.8 (95% CI:
1.7–1.9) for usual activity, 2.3 (95% CI: 2.2–2.4) for pain/
discomfort and 2.7 (95% CI: 2.6–2.8) for anxiety/depres-
sion (additional file 2). “No problems” were reported by
62% for mobility, 85% for self-care, 58% for usual activ-
ities, 36% for pain/discomfort, and only 23% for anxiety/
depression. This means that the majority of patients had
no problems with mobility and conducting usual activ-
ities and self-care. On the other hand, extreme prob-
lems” with pain/discomfort were noted by 5 % and 7 %
reported “extreme problems” with anxiety/depression.
Under 1 % reported “extreme problems” with mobility,
self-care and usual activities. Females and patients re-
ceiving methadone treatment reported more problems
across all EQ-5D-5L domains compared to males and
patients on buprenorphine-based medications, respect-
ively. Patients in the age group 41–60 reported more
Table 1 Baseline characteristics of study sample
Percentages or Mean
(SD)
Patients, na
Gender, n = 609
Male 71%
Female 29%
Age, n = 609
< 25 3%
26–40 39%
41–60 53%
≥ 61 5%
Mean age (SD) 44 (10)
Current OAT medication, n = 588
Methadone 38%
Buprenorphine 56%
Buprenorphine/naloxone 4%
Other 2%
Duration of OAT treatment in years, mean
(SD), n = 583
7.9 (5.4)
Background demographics
Highest level of completed education, n = 588
Did not complete primary and secondary
school
5%
Completed primary and secondary school 45%
High school 40%
Undergraduate education ≤3 years 8%
Postgraduate education ≥3 years 2%
Main source of income, several answers possible, n = 611
Paid work (full time or part time) 7%
Sick pay or unemployment benefits 10%
Social or disability benefits 79%
Savings or scholarships 1%
Other 3%
Accommodation last 30 days several answers possible, n = 606
Owned property 9%
Rented property 68%
Temporary property 7%
Prison 1%
Homeless 1%
At friends or family 12%
Other 2%
Living conditions n = 586
Living alone 63%
Living with others 37%
Children n = 587
Do not have children 44%
Table 1 Baseline characteristics of study sample (Continued)
Percentages or Mean
(SD)
Have children 56%
For those having children < 18 years old, n = 152
Having children < 18 with visiting rights 79%
Having children < 18, but no visiting rights 21%
OAT Opioid agonist therapy, SD Standard deviation,
an = number of respondents, some questions allow multiple answers
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problems on every domain except pain/discomfort com-
pared to patients under 40 years of age, while patients
over 60 years of age reported most problems for mobility
and pain/discomfort (additional file 2).
The mean (SD) EQ-5D-5L index value for OAT patients
was 0.699 (0.250) at baseline. Forty-three percent had an
index value above 0.8, meaning they had “no problems” in
the five health domains. Thirty-four percent of the sample
even had an index value above 0.848 (Norwegian reference
population [40]), meaning their HRQoL was better than
that of the Norwegian general population. Around 5 %
had an index value below 0.2, meaning they had “extreme
problems” in HRQoL. The distribution in baseline EQ-
5D-5L index values are shown in the Pen’s Parade (Fig. 2).
The parade shows the HRQoL distribution, and is defined
as a succession of every OAT patient included, with their
height proportional to their EQ-5D-5L index value, from
lowest to highest.
The mean (SD) EQ-VAS score of OAT patients was
57 (22) for the total sample at baseline, meaning their
Fig. 1 Proportion of individuals reporting problems by EQ-5D-5L domain; overall, by age, gender and OAT medication. OAT = opioid agonist
therapy. Altogether 609 respondents, 8 patients missed values on one dimension. 11 patients, which did not receive either methadone or
buprenorphine-based medications are left out of the illustration but not analysis. Proportions (%) and dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression). 1A: Overall, 1B: Gender 1C: OAT medication 1D: Age groups
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self-perceived health was considerably lower compared
to the Norwegian reference population of 80 (19) [40].
Females reported an EQ-VAS of 56 (23), while 54 (22)
for patients aged 41–60, and 51 (23) for patients older
than age 60. Patients on methadone reported 53 (22),
which was lower EQ-VAS compared to buprenorphine
with 58 (22) and buprenorphine-naloxone 65 (21).
Changes in HRQoL of OAT patients at follow up
Altogether 245 (40%) of the 609 patients at baseline
were included for the follow-up analyses. As shown in
the Pen’s Parade (Fig. 2), individual changes in EQ-5D-
5L index values for patients with follow-up data (n =
245) are indicated with vertical lines. For instance, a pa-
tient with an index value of 0.563 at baseline and a long
vertical line going up to 0.840 at follow-up means this
patient reported a significant improvement in HRQoL. A
patient with a vertical line going down from baseline
shows worsen HRQoL between baseline and follow-up.
Patients with no follow-up data (n = 364) or no change
at follow-up (n = 26) has no vertical line. Figure 2 also
shows that the majority of patients have a lower index
value than the Norwegian reference population, meaning
worse HRQoL, illustrated by values below the dotted
line. However, changes go in both directions and appear
substantial for some. This means that patients receiving
long-term OAT are at risk of relatively rapid changes in
index values in both better and worse directions. Over-
all, around 54% reported improvement in HRQoL,
around 35% reported worse HRQoL while 11% reported
no changes at follow up compared to baseline values.
The mean (SD) observed change was 0.038 (0.20) with
minimum and maximum values of − 0.646 and 0.639, re-
spectively. Females reported a mean (SD) change of
0.056 (0.17) compared to males 0.032 (0.21). Variation
in individual EQ-5D-5L index value changes from base-
line to follow-up is illustrated in additional file 3.
EQ-5D-5L index values improved significantly overall
(p = 0.004) and for both genders (m: 0.039, f: 0.016), age
group 26–40 (p = 0.002) and buprenorphine-based pa-
tients (p = 0.027) as shown in Table 2. The mean (SD)
EQ-5D-5L index value was 0.729 (0.237) at follow-up;
49% had an index value above 0.8 while 37% of the sam-
ple had an index value above the Norwegian reference
population. Around 4 % had an index value below 0.2.
Significant improvements in EQ-5D-5L scores were
found for mobility (p = 0.008) and pain/discomfort (p =
0.025) (Fig. 3 and Table 3).
Significant improvement in self-perceived health (EQ-
VAS) were found for males (p = 0.038).
Discussion
This study is one of the first to examine changes in
HRQoL in a sample of long-term OAT patients over a
one-year follow-up period. Most studies on HRQoL
demonstrate improvements in HRQoL upon treatment
entry, but data on long-term patients’ HRQoL is scarce.
Considerable impairments in HRQoL and self-perceived
health (EQ-VAS) were found in many of the OAT pa-
tients. However, large variations in EQ-5D-5L index
values were found between individuals, both at baseline
and at follow-up. Significant improvement in overall
HRQoL was observed at one-year follow-up with around
half of the OAT patients reported some improvement in
HRQoL while around one-third experienced worse
HRQoL at one-year follow up, with great individual vari-
ations. Males reported significant improvement in their
self-perceived health.
Compared to the general Norwegian population,
which reported no problems regarding mobility (85%),
self-care (98%), usual activities (82%), pain/discomfort
(54%) and anxiety/depression (79%) [40], OAT patients
reported in average consistently higher percentages of
problems across all EQ-5D-5L domains, especially pain/
discomfort and anxiety/depression where only 36 and
23% respectively, reported no problems. The mean (SD)
EQ-5D-5L index value for the Norwegian reference
population 0.848 (0.200) [40] was considerably higher
compared to the OAT patients at baseline. Mean (SD)
total EQ-VAS for the OAT patients at baseline was con-
siderably lower than the Norwegian reference population
who reported overall mean (SD) of 80 (19); females 80
(20) and older age 77 (19) [40].
Our findings are consistent with prior research, such
as Strada et. al (2019) study of a large OAT cohort in
Germany; found that OAT patients had a lower HRQoL
than the general population [41]. Several studies have
demonstrated that female OAT patients report worse
overall HRQoL compared to males [8, 27]. However it is
unclear why that is the case and gender-focused research
is urgently needed. Perhaps females are more vulnerable
for stigma, traumatizing events or maybe have a poorer
function upon entering OAT in the first place. Age is
also strongly correlated to poor physical HRQoL [41]. In
our sample the mean age was 44, which is consistent
with an aging OAT population in Norway [32, 42]. In-
creased age of OAT patients coupled with poorly re-
ported HRQoL, may place an increased demand for
health care services in the future. This raises a debate on
how level of OAT and various integrated treatment pol-
icies and strategies could better benefit OAT patients.
Even if OAT patients treated with methadone reported
worse HRQoL than those with buprenorphine, the re-
sults should be interpreted carefully. In current Norwe-
gian OAT guidelines buprenorphine is usually
recommended as first line substitution medication and
considered safer compared to methadone due to its par-
tial antagonistic effect [43]. It is also likely that patients
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may prefer buprenorphine because it is less sedative
than methadone, and that both younger and perhaps
more stable patients are dispensed buprenorphine, and
as such, results could be highly confounded.
Previous research has revealed that HRQoL improves
considerably at OAT treatment initiation and the first
few months [44]: however, not much research to date
has investigated the long-term effect of OAT on pa-
tients’ HRQoL [7, 22, 29]. For instance, one study among
patients on methadone maintenance treatment found
that QoL increased markedly in the beginning of the
observation, but decreased after 6 months [45] while
other studies only saw improvements in the beginning of
observation [27, 46]. There is therefore the general be-
lief, based on limited data, that once patients are en-
rolled in OAT, their HRQoL will remain low and does
not change substantially anymore. Our study challenges
that belief and is among the first to show that changes
in HRQoL, including positive changes, are possible.
Additionally, our findings also show that many patients
had extreme variations in index values from baseline to
follow-up, in both positive and negative directions. This
Fig. 2 Pen’s Parade: distribution from lowest to greatest health. Pen’s Parade: The distribution in baseline EQ-5D-5L index values, where 43% had
> 0.8 and 5% had < 0.2 at baseline. The dotted line represent the average reported index value of the Norwegian reference population
Table 2 OAT patients’ HRQoL and self-perceived health at baseline and follow up as measured by the EQ-5D-5L
EQ-5D-5L VAS, baseline EQ-5D-5L VAS, baselinea EQ-5D-5L VAS, follow-up EQ-5D-5L Index EQ-5D-5L Index EQ-5D-5L Index
n 609 n 245 n 245 n 609, baseline n 245, baselinea n 245, follow-up
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Overall 57 22 57 22 59 22 0.699 0.250 0.691 0.237 0.729 0.237
Gender
Female 56 23 57 25 57 23 0.653 0.260 0.613 0.273 0.669 0.261
Male 57 22 57 21 60 22 0.718 0.243 0.716 0.220 0.748 0.226
Age group
< 25 58 18 55 19 61 25 0.787 0.164 0.766 0.211 0.678 0.390
26–40 61 22 59 22 60 22 0.724 0.242 0.689 0.234 0.745 0.205
41–60 54 22 55 22 58 22 0.684 0.253 0.686 0.238 0.716 0.253
≥61 51 23 56 16 58 16 0.613 0.292 0.714 0.257 0.754 0.210
OAT medication
Methadone 53 22 54 21 58 23 0.636 0.260 0.657 0.228 0.686 0.236
Buprenorphine 58 22 58 22 60 22 0.726 0.235 0.716 0.238 0.758 0.232
Buprenorphine/
naloxone
65 21 59 30 54 26 0.775 0.242 0.558 0.352 0.737 0.335
OAT Opioid agonist therapy, SD Standard deviation
Index obtained from Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2018. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England.
Health Economics
aBaseline values for the 245 patients who were eligible for follow-up analysis
The possible range of scores for EQ-5D-5L (0–1, 0 = dead (scores < 0 is possible), 1 = full health) and EQ-VAS (0–100, 0 = worst health imaginable, 100 = best
health imaginable
Statistically significant changes are marked in bold (p < 0.05)
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suggests that OAT populations are susceptible to severe
impairment and also rapid improvements in their
HRQoL. Such swift alterations are perhaps less common
among other patient groups and future research should
examine what causes these changes in HRQoL in long-
term OAT patients.
HRQoL in the long-term OAT population was lower
in average compared to what is found in other patient
groups, such as diabetes type 1 and 2 [47], HIV/AIDS
patients [48] and patients with psychiatric comorbidities
such as mild to moderate anxiety and depressive disor-
ders, and residual state of bipolar disease [49]. Using the
inverse of disability weights (health state valuations) re-
ported in the Global Burden of Disease study (2017),
makes comparisons between HRQoL index values and
disability weights possible [50]. Research have shown
there is a high comorbidity of psychiatric disorders
among people with substance use disorders and individ-
uals on OAT [11, 12, 16], while a six-year follow-up
study demonstrated that the high psychiatric comorbid-
ity persisted in long-term OAT patients [51]. This may
have severe HRQoL impacts and patients with mental
disorders may therefore be overrepresented in the lower
extreme of the reported index values. Given the wide
distribution of severity of disease within the long-term
OAT population, treatment needs to be individualized
and better adapted to patient functioning and needs.
This opts for rethinking and reassessing OAT programs
to better facilitate for integrated treatment, which have
found to be consistently superior to treatment of sub-
stance use and mental disorders with separate treatment
plans [52].
Furthermore, as HRQoL profiles of OAT patients are
diverse and dynamic this has implications for personal-
ized patient care and the need for regular assessment of
HRQoL as an outcome. We need to better understand
what drives the extreme and rapid changes in HRQoL in
both positive and negative directions among OAT pa-
tients. We need to know how to best prevent large drops
in index score and how to increase and maintain the in-
creases in index score over time. Additionally, females
have worse HRQoL scores compared to men, which in-
dicates that OAT programs should particularly focus on
how to improve HRQoL of females and find explana-
tions for why females have lower HRQoL. Similarly, we
found that patients older than 40 years have worse
Fig. 3 EQ-5D-5L domains at baseline versus follow-up. OAT = opioid agonist therapy. Proportions (%) and dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression). Baseline and follow-up for the 245 patients who were eligible for follow-up analysis
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HRQoL. This shows that we need to re-examine health
care needs of older patients are met and how we can ad-
dress their needs better. This is particularly important as
long-term OAT patients are now aging and we need to
plan for aging populations receiving OAT.
A strength of this study is the large sample size of
long-term OAT patients at baseline who are receiving
the same level of integrated OAT treatment across their
respective OAT outpatient clinics in the two cities.
However, there are also limitations to our study. Follow-
up was conducted on a sub-group of the initial sample.
To reduce the selection bias due to the loss-to-follow-up
we performed an inverse probability weighted method.
In general, it is problematic to compare HRQoL between
studies as setting, population, and level of OAT inte-
grated treatment varies and different instruments are be-
ing used. This is also the case for comparisons between
results based on EQ-5D-3L and EQ-5D-5L, and when
different national value sets are being used. Comparative
performance across patient groups is driven by differ-
ences in the descriptive systems and associated value
sets [37] Another weakness is the absence of a
Table 3 Distribution of EQ-5D-5L dimensions at baseline and at follow-up
Mean time between baseline and follow-up is 375 days (95% CI: 358,6–391.9)
Baseline: 609 patients Follow-up: 245 patients
Dimension Baseline Baselinea Follow-up p value
Mobility mean (95% CI) 1.7 (1.6–1.8) 1.7 (1.5–1.8) 1.5 (1.4–1.6)
No problems n (%) 378 (62.1) 149 (60.8) 170 (69.4) 0.0081
Slight problems n (%) 119 (19.5) 53 (21.6) 40 (16.3)
Moderate problems n (%) 49 (8.1) 23 (9.4) 21 (8.6)
Severe problems n (%) 59 (9.7) 18 (7.4) 14 (5.7)
Unable to walk about n (%) 3 (0.5) 2 (1.0) 0 (0)
Self-care mean mean (95% CI) 1.3 (1.2–1.3) 1.3 (1.2–1.4) 1.2 (1.2–1.3)
No problems n (%) 517 (84.9) 202 (82.5) 204 (83.3) 0.4
Slight problems n (%) 56 (9.2) 27 (11.0) 29 (11.8)
Moderate problems n (%) 18 (2.9) 9 (3.7) 8 (3.3)
Severe problems n (%) 15 (2.5) 7 (2.9) 4 (1.6)
Unable to wash or dress n (%) 2 (0.2) 0 (0) 0 (0)
Usual activities mean (95% CI) 1.8 (1.7–1.9) 1.9 (1.8–2.1) 1.8 (1.6–1.9)
No problems n (%) 350 (57.5) 120 (49.0) 142 (58.0) 0.1
Slight problems n (%) 129 (21.1) 69 (28.2) 45 (18.4)
Moderate problems n (%) 64 (10.5) 23 (9.4) 32 (13.1)
Severe problems n (%) 58 (9.5) 27 (11.0) 24 (9.8)
Unable to do usual activities n (%) 5 (0.8) 5 (2.0) 2 (0.8)
Pain/discomfort mean (95% CI) 2.3 (2.2–2.4) 2.2 (2.1–2.4) 2.1 (1.9–2.2)
No pain/discomfort n (%) 218 (35.8) 90 (36.7) 109 (44.5) 0.0245
Slight pain/discomfort n (%) 142 (23.3) 58 (23.7) 53 (21.6)
Moderate pain/discomfort n (%) 127 (20.9) 53 (21.6) 47 (19.2)
Severe pain/discomfort n (%) 92 (15.1) 35 (14.3) 29 (11.8)
Extreme pain/discomfort n (%) 29 (4.8) 9 (3.7) 7 (2.9)
Anxiety/depression mean (95% CI) 2.7 (2.6–2.8) 2.7 (2.6–2.9) 2.7 (2.5–2.8)
Not anxious/depressed n (%) 137 (22.5) 48 (19.6) 63 (25.7) 0.3
Slightly anxious/depressed n (%) 157 (25.8) 66 (26.9) 46 (18.8)
Moderately anxious/depressed n (%) 136 (22.3) 56 (22.9) 64 (26.1)
Severely anxious/depressed n (%) 132 (21.7) 51 (20.8) 56 (22.9)
Extremely anxious/depressed n (%) 45 (7.4) 24 (9.8) 16 (6.5)
CI Confidence interval
P-value: based on paired t-test of means for the 245 patients with two time points
aBaseline values for the 245 patients who were included for follow-up analysis
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Norwegian value set. Both our study and the study of
the Norwegian reference population had to use value
sets that resembles the Norwegian population, and for
this reason the UK value set was chosen. Studies have
confirmed that the latter version of EQ-5D significantly
increase both reliability and sensitivity and can poten-
tially reduce the possible ceiling effects encountered in
the EQ-5D-3L earlier version [53, 54].
Conclusion
We found considerably lower HRQoL among long-term
OAT patients in average compared to the general Nor-
wegian reference population. However, this is a hetero-
geneous population. Around one-third had very good
HRQoL, higher than average Norwegian values. Im-
provements in HRQoL were found over the one-year
follow-up across most EQ-5D-5L dimensions with some
uncertainties on why this was seen. More research is ur-
gently needed to identify and understand why females
and older patients have worse HRQoL and shows there
is a need for more gender-and age-specific treatment in
OAT programs. The wide variations in HRQoL support
more emphasis on individualized treatment and person-
alized patient care, and the need for regular assessment
of HRQoL in OAT programs. Our study is among the
first to show that changes in HRQoL, including positive
changes, are possible even several years after initiation of
treatment. Future research should examine what causes
these changes in HRQoL in long-term OAT patients.
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